- Home
- SJT vs RCEL Comparison
SJT vs RCEL Comparison
Compare SJT & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- RCEL
- Stock Information
- Founded
- SJT 1980
- RCEL N/A
- Country
- SJT United States
- RCEL United States
- Employees
- SJT N/A
- RCEL N/A
- Industry
- SJT Oil & Gas Production
- RCEL Medical/Dental Instruments
- Sector
- SJT Energy
- RCEL Health Care
- Exchange
- SJT Nasdaq
- RCEL Nasdaq
- Market Cap
- SJT 270.3M
- RCEL 240.6M
- IPO Year
- SJT N/A
- RCEL N/A
- Fundamental
- Price
- SJT $6.39
- RCEL $9.33
- Analyst Decision
- SJT
- RCEL Strong Buy
- Analyst Count
- SJT 0
- RCEL 4
- Target Price
- SJT N/A
- RCEL $17.25
- AVG Volume (30 Days)
- SJT 288.9K
- RCEL 150.5K
- Earning Date
- SJT 05-20-2025
- RCEL 05-08-2025
- Dividend Yield
- SJT N/A
- RCEL N/A
- EPS Growth
- SJT N/A
- RCEL N/A
- EPS
- SJT 0.11
- RCEL N/A
- Revenue
- SJT $7,032,254.00
- RCEL $64,251,000.00
- Revenue This Year
- SJT N/A
- RCEL $62.33
- Revenue Next Year
- SJT N/A
- RCEL $30.59
- P/E Ratio
- SJT $56.38
- RCEL N/A
- Revenue Growth
- SJT N/A
- RCEL 28.14
- 52 Week Low
- SJT $3.21
- RCEL $6.90
- 52 Week High
- SJT $6.51
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- SJT 68.16
- RCEL 51.51
- Support Level
- SJT $6.03
- RCEL $9.50
- Resistance Level
- SJT $6.35
- RCEL $10.29
- Average True Range (ATR)
- SJT 0.29
- RCEL 0.49
- MACD
- SJT 0.04
- RCEL -0.05
- Stochastic Oscillator
- SJT 88.00
- RCEL 34.25
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.